#USA #San Francisco #InsightRX #KLAS #precision dosing

InsightRX Achieves Impressive KLAS Performance Score

In an impressive achievement for the healthcare technology sector, InsightRX has been recognized as a trailblazer in precision dosing solutions with a remarkable performance score of 96.1 in the KLAS Spotlight 2025 report. This score positions InsightRX among the top-rated vendors in clinical decision support, validating its excellence in enhancing clinician experiences, ensuring seamless electronic health record (EHR) integration, and delivering significant patient outcomes.

The Significance of KLAS Recognition

KLAS, an organization recognized for its role in evaluating healthcare technology vendors, provides insights based on independent surveys of healthcare providers. InsightRX stands out as the first pharmacy-focused precision dosing solution to receive such high acclaim in the Emerging Company Spotlight report for 2025.

Performance Highlights

InsightRX's overall score of 96.1 far exceeds the Best in KLAS average of 80.6%. The report highlights several key categories in which InsightRX excels:

• - Supports Integration Goals: A+
• - Product Functionality: A-
• - Executive Involvement: A+
• - Likelihood to Recommend: A+

Additionally, patient care outcomes attributed to InsightRX's system include:

• - Reduced medication side effects.
• - Enhanced therapeutic target attainment.
• - Decrease in acute kidney injury rates.

The outcomes noted were achieved within just six months of adopting the InsightRX system, showcasing its profound impact on patient care in those early stages.

Testimonials from Pharmacy Leaders

Feedback from pharmacy managers highlights the practical benefits of integrating the InsightRX system:

• - “The system dropped our rate of kidney injury for patients on certain antibiotics. Our estimate is that the system ultimately saves us hundreds of thousands of dollars a year.”
• - Another manager noted, “The integration with the EHR is InsightRX's strength. We get real-time, immediate dosing recommendations.”

Future Developments: Next-Generation Clinical Decision Support

While the KLAS report solidifies InsightRX's leadership in precision dosing and clinical decision support, the company has ambitious plans for the future. It aims to expand its platform to include new drug classes and therapeutic areas, with a focus on developing its upcoming agentic AI system. This next-gen tool intends to integrate pharmacokinetics/pharmacodynamics (PK/PD) modeling with extensive clinical context. By doing this, InsightRX plans to provide even more actionable insights that help optimize stewardship programs, improve antimicrobials, and integrate genomic data into routine care pathways.

Leadership Vision and Company Background

Dr. Sirj Goswami, CEO and Co-Founder of InsightRX, stated, “We are honored to be recognized by KLAS with one of the highest scores in the clinical decision support category. Their reputation is unmatched, and this validation reflects the measurable impact our platform is already having in precision dosing. Our vision is to expand precision dosing to new drug classes and therapeutic areas.”

Founded as a healthcare technology company, InsightRX provides a cloud-based precision dosing platform that utilizes pharmacokinetic models, real-world data, and advanced machine learning algorithms. This empowers clinicians to make individualized therapy decisions across various critical therapeutic areas, such as infectious diseases, bone marrow transplants, and more.

To learn more about InsightRX and its innovative solutions, visit www.insight-rx.com.